126 results about "Mannuronic acid" patented technology

The invention discloses a sodium alginate oligosaccharide coated slow-release fertilizer. Coated materials of the slow-release fertilizer contain sodium alginate oligosaccharide and an auxiliary coated material, wherein sodium alginate oligosaccharide is composed of two structural units, namely a-L-mannuronic acid and b-D-guluronic acid. The two structural units are linked in three ways by 1,4-glucosidic bond, so as to form a unbranched linear segmented copolymer. The coated slow-release fertilizer is mainly applied in commercial crops, fruit and vegetable crops, grain crops, economic forest, flowers and plants, traditional Chinese medicinal materials, lawn and the like. By introducing organism-derived sodium alginate oligosaccharide into the coated materials of the slow-release fertilizer, nutritive elements required by plant growth and development can be supplemented by a slow-release approach, and the plant growth promoting effect of sodium alginate oligosaccharide also can be performed so as to finally achieve the yield-increasing effect. In addition, a medicament prepared by using sodium alginate oligosaccharide as the main coated material composition is safe and nontoxic and has advantages of low cost, small application amount and the like.

The invention discloses a leaf fertilizer composition comprising sodium alginate oligosaccharide, which is characterized in that the composition comprises sodium alginate oligosaccharide, amino acid and microelements that can promote plant growth significantly, wherein sodium alginate oligosaccharide is also known as sodium alginate, sea-tangle glue and algin, is natural polysaccharide carbohydrate extracted from sea tangle, and is a copolymer comprising a-L-mannuronic acid (M), b-D-guluronic acid (G) connected with a-L-mannuronic acid (M) by 1,4-glycosidic bond, and different GGGMMM fragments; a molecular formula is (C6H7O6Na)n; the degree of polymerization is 2-10; the uronic acid constitution M / G is equal to 7:3; the uronic acid content is greater than 90%, and is 2-3% of the total content; the content of a microelement leaf fertilizer is 2-20%; and the microelement leaf fertilizer comprises at least two of sulfur, boron, ferrum, manganese, copper, zinc and molybdenum. The composition is mainly applicable to industrial crops, fruit and vegetable crops, grain crops, economic trees, flowers, lawns and the like.

The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The present invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedures that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2-6 and the temperature of 100-120° C., and pH is adjusted to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative degradation product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.

The invention relates to a method for extracting active polysaccharides from brown algae. The method comprises the following specific steps of: putting a cleaned, dried and smashed alga raw material into an extraction container, and adding an organic acid solution or organic-inorganic mixed acid solution; heating a stirred and wetted material to 50-150 DEG C to realize partial degradation of highpolymer polysaccharide substances of brown algae; fully washing with an organic solvent till the acid solution in the material is discharged completely; adding 5-8 times of volume of water for extracting, concentrating an extracting solution, regulating the PH value to neutral, and gradually depositing in alcohol to obtain align, fucoidin and laminaran which are rich in mannuronic acid fragments (rich in M) respectively; and pretreating brown alga raw material residues with water-extracted organic acid according to an alkali digestion process to obtain align which is rich in guluronic acid fragments (rich in G). By adopting the method, the defects of high water consumption, severe pollution and the like existing in the conventional align production process are overcome; and the method has the advantages of saving in energy, reduction in emission, high product yield, small extraction solvent dosage, and the like.

The invention relates to a method for preparing algin oligosaccharide by using algin lyase Agarivorans albus YKW-34, which is characterized by comprising the following steps: firstly preparing enzyme liquid of the algin lyase Agarivorans albus YKW-34, dissolving algin in water, adding the prepared enzyme liquid into the solution, decomposing the algin for 2 to 180 hours in a water bath at a temperature of 20 to 55 DEG C, raising the temperature to between 60 and 100 DEG C, inactivating the algin, filtering the algin by a film, and condensing, freezing and drying the algin to obtain the algin oligosaccharide. The method has the advantages that a culture medium for preparing the algin lyase has economic and simple compositions; the algin lyase has high yield, unique Na<+> / K<+> ion dependence, superior temperature and pH stability and high specific activity, and can degrade seminose half aldehyde and guluronic acid fragments of the algin at the same time; and the produced algin oligosaccharide with the polymerization degree of 2 to 12 has favorable application prospect.

The invention relates to application of mannuronic acid oligose with carboxyl at a 1-position of a reducing end and a derivative to treatment of a Parkinson's disease. The mannuronic acid oligose and the derivative are particularly a compound or a pharmaceutically acceptable salt expressed by the following structural formula (II) in the description, wherein n in the formula (II) is one or more integers from 0-20.

The present invention provides algin oligosaccharides having polymerized degree of 2-22 and the derivatives thereof, such algin oligosaccharides are made of mannuronic acid bonded by [proportional to]-1,4 glycosidic bond. The derivatives which the reduced terminal in position-1 is carboxyl radical can be obtained by oxidation. The invention also provides the manufacture of algin oligosaccharides and the derivatives thereof, which includes the alginate solution in water reacts in the reactor under the condition of high press, 100-120 DEG C, pH2-6, for 2-6 hours, after the reaction completed, its pH value was adjusted to 7. The result oligosaccharides are oxidated in presence of the oxidant, and then produces the oxidated products. The algin oligosaccharides and the derivatives thereof of the invention can be used in the manufacture of medicaments for preventing Alzheimer's dementia and diabetes.

The present invention is directed to a composition comprising high mannuronic acid-containing alginate and a polycation having a polydispersity index of less than 1.5. The composition is particularly useful for making biocompatible microcapsules containing living cells for allo- or xeno-transplantation. Such microcapsules have enhanced durability and can maintain their structural and functional integrity over long periods of time compared to prior art alginate microcapsules.

The present invention discloses an alginic acid and / or its salts with low molecular weight, wherein the weight average molecular weight of the alginic acid is from about 700 to about 4500 Daltons, and the molar ratio of guluronic acid to mannuronic acid in the alginic acid is from about 0.6 to about 19. The present invention also discloses the preparative method of making the alginic acid and / or its salts thereof, and the use of them for treating hypertension, chronic renal failure and postprandial hyperglycemia induced by glycosidase. The present invention further discloses pharmaceutical compositions and foods containing the alginic acid with low molecular weight and / or salts thereof as active component.

The invention relates to application of sodium alginate oligose and a derivative to treatment of pain. The sodium alginate oligose and the derivative of the sodium alginate oligose are particularly mannuronic acid oligose or mannuronic acid oligose with a carboxyl at a 1-position of a reducing end and the derivative or a pharmaceutically acceptable salt, formed by connecting a beta-D-mannuronic acid through a 1,4-glucosidic bond.

Bacterial polynucleotides and polypeptides are provided in which the polypeptides have a dehydrogenase activity, such as an alcohol dehydrogenase (ADH) activity, an uronate, a 4-deoxy-L-erythro-5-hexoseulose uronate (DEHU) ((4S,5S)-4,5 dihydroxy-2,6-dioxohexanoate) hydrogenase activity, a 2-keto-3-deoxy-D-gluconate dehydrogenase activity, a D-mannuronate hydrogenase activity, and / or a D-mannnonate dehydrogenase activity. Methods, enzymes, recombinant microorganism, and microbial systems are also provided for converting polysaccharides, such as those derived from biomass, into suitable monosaccharides or oligosaccharides, as well as for converting suitable monosaccharides or oligosaccharides into commodity chemicals, such as biofuels. Commodity chemicals produced by the methods described herein are also provided.

The invention relates to application of sodium alginate oligose and a derivative to treatment of vascular dementia. The sodium alginate oligose and the derivative of the sodium alginate oligose are particularly mannuronic acid oligose or mannuronic acid oligose with a carboxyl at a 1-position of a reducing end and the derivative or a pharmaceutically acceptable salt, formed by connecting a beta-D-mannuronic acid through a 1,4-glucosidic bond.

The invention relates to application of sodium alginate oligose and a derivative to treatment of inflammations. The sodium alginate oligose and the derivative of the sodium alginate oligose are particularly mannuronic acid oligose or mannuronic acid oligose with a carboxyl at a 1-position of a reducing end and the derivative or a pharmaceutically acceptable salt, formed by connecting a beta-D-mannuronic acid through a 1,4-glucosidic bond. The inflammations are particularly a vascular inflammation, a neuroinflammation, a nervous centralis inflammation, arthritis, Crohn's disease, ulcerative colitis, inflammatory diabetic ulcer, psoriasis, atopic dermatitis and eczema.

The invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedure that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2˜6 and the temperature of 100˜120° C., and adjusted pH to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.

The invention provides essence cream realizing repairing at night. The essence cream realizing repairing at night comprises allantoin, EDTA-2NA, acrylic acid (ester) / C10-30 alkanol acrylate cross-linked polymer, hyaluronic acid, hydrogenated polyisobutene, cetyl ethyl hexanoate, glyceryl stearate / PEG-100 stearate, polydimethylsiloxane, C14-22 alcohol / C12-20 alkyl glucoside, shea butter oil, tocopherol acetate, polydimethylsiloxane / dimethiconol, methyl silanol mannuronic acid ester / sodium methyl hydroxybenzoate / sorbic acid / propyl hydroxybenzoate, water / butanediol / 1,2-hexanediol / beta-glucan / phenoxyethanol, water / phenoxyethanol / algae extract, nicotinamide, water / propylene glycol / flos buddlejae extract, and dipotassium glycyrrhizinate. The essence cream belongs to emulsified ointment essencewith the efficacies of repairing skin injuries and realizing the moisturizing effect. The essence cream system realizing repairing at night is stable, realizes permeation and absorption easily, is refreshing but not greasy, can effectively repair injuries caused to the skin by sunlight, can balance the skin color, can resist skin ageing, realizes effective moisturizing, and realizes regenerating and nursing at night.

This invention relates to an extraction process of brown algae polysaccharides in a field of pharmaceutical chemistry. This invention particularly discloses a process of extracting brown algae polysaccharides based on a microwave chemistry method and brown algae polysaccharides obtained by said process. The process of the invention comprises: 1) putting pulverized brown algae powder into a microwave reaction chamber, adding acid solution to conduct reaction; optionally concentrating the mixer, and then washing with organic solvent to remove excess acid; conducting grading alcohol precipitation after water extract to obtain mannuronic acid rich fragment (M rich) algin, fucoidan and / or laminaran respectively; and adding an alkali solution to the brown algae residue to conduct alkaline digestion, filtering the residue off, adjusting pH of the filtrate to neutral, conducting alcohol precipitation to obtain guluronic acid rich fragment (G rich) algin precipitates. The present invention has significant advantages like fast processing rate, high yield of polysaccharides, strong controllable polysaccharide degradation, using less organic acid and efficient recovery, small water consumption, low power consumption, etc., the active polysaccharides has high yield and content, better water-soluble, and good biological activities.

A preparation method for alginate oligosaccharides includes following steps: adding the water to the alginic acid or metal salt or the produced high mannuronic acid, high guluronic acid section to dissolve or disperse in the water, adding it to the oxidant solvent in a radiation condition, heating the solution to 60-80 DEG C for 4-50 minutes, then cooling the solution, concentrating the solution by nanofiltration film, drying the concentrated liquid by spray. The invention improves the product quality by preventing the product over-oxidation by the radiation assistance in a lower temperature; effectively reduces the dosage of the oxidant by controlling the product degree of polymerization distribution in a low reaction temperature; avoids using organic solvent, reduces the product costs and saves the cost by nanofiltration film separation technique and spary drying technique which can be achieve the industry mass production. Therefore, the method has a practical application value.

The invention relates to an algin oligosaccharide diacid combination. The algin oligosaccharide diacid combination contains D-mannuronic acid or pharmaceutically-accpetable salt thereof in formula (III), wherein n is selected from an integral number from 1-9, m is selected from 0,1 or 2, m' is selected from 0 or 1, besides, the total weight of the algin oligosaccharide diacid of which n=1-5 is 60%or above of the total weight of the combination, and the total weight of L-guluronic acid is 50% or below of the weight of the composition.

The invention discloses a method for in-vitro amplification of tumor stem cells. The method comprises the following steps of carrying out in-vitro three-dimensional culture on tumor cells by an alginate gel support, and adjusting and controlling the rigidity of the alginate gel support by a change of support preparation parameters such as alginate molecular weight, a ratio (GM) of guluronic acid content to mannuronic acid content, a calcium ion concentration and calcification time, so that hardness of an in-vitro matrix in different tumor tissue microenvironments is simulated and in-vitro amplification of tumor stem cells in different tissue is realized. The method can be operated simply, has a low cost and controllable performances, can be industrialized and is a good method for in-vitro amplification on tumor stem cells having different sources.

The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The present invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedures that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2-6 and the temperature of 100-120° C., and pH is adjusted to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative degradation product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.

The invention relates to facultative incision type recombinant alginate lyase rAly-1 as well as a coding gene and application thereof. An amino acid sequence of the facultative incision type recombinant alginate lyase rAly-1 is as shown by SEQ ID NO. 2; a nucleotide sequence of the coding gene of the facultative incision type recombinant alginate lyase rAly-1 is as shown by SEQ ID NO. 1. According to the facultative incision type recombinant alginate lyase rAly-1 as well as the coding gene and the application thereof, the facultative incision type recombinant alginate lyase rAly-1 is obtained from a genome of flammeovirga yaeyamensis MY04 for the first time; not only can the lyase be used for degrading a guluronic acid segment from alginate, but also can be used for degrading a mannuronic acid segment. The lyase can be used for thoroughly degrading alginate polysaccharide in any M / G ratio, and efficiently preparing alginate oligosaccharide with a lower polymerization degree.

The invention provides a use of low-molecular weight oligomannuronate in preparation of a drug or a health care product for preventing or treating Parkinson's disease. According to the invention, marine acidic polysaccharose as a raw material is prepared into a water-soluble low-molecular weight mannuronic acid compound. An experiment proves that the low-molecular weight mannuronic acid can be used for preventing and treating or improving Parkinson's disease, has obvious pharmacological effects and no toxic or side effects on nerve cells and can be taken for a long time. The low-molecular weight mannuronic acid is a marine natural product, has the advantages of rich resources, easy industrialization, high safety, unique structure and good oral absorption, and has a wide market application prospect in prevention and treatment of Parkinson's disease.

The invention belongs to the field of marine drugs and particularly relates to the application of mannan-oligosaccharide aldehyde acid salt in preparing a medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis. The mannan-oligosaccharide aldehyde acid salt is used for preparing the medicine for protecting livers and curing various hepatitis, liver fibrosis or cirrhosis. The mannan-oligosaccharide aldehyde acid salt takes algin as a raw material, through a chemical degradation method or a physical degradation method, or the combination of the two degradation methods, mannan-oligosaccharide aldehyde acid with different molecular weights can be obtained; the mannan-oligosaccharide aldehyde acid is prepared through neutralization into lithium salt, sodium salt, kali salt, calcium salt or magnesium salt of the mannan-oligosaccharide aldehyde acid with different molecular weights, the molecular skeleton of the mannan-oligosaccharide aldehyde acid adopts a linear oligosaccharide compound formed by connecting D-mannuronic acid (M) through a Beta-1, 4 glucosidic bond. The product in the invention is derived from algal polysaccharides, has the advantages of rich resources, easiness in industrialization, safety, effectiveness and the like, and has a wide development and application prospect in preventing and curing liver damage, and various hepatitis, liver fibrosis and cirrhosis.

The invention provides applications of poly mannuronic acid propyl ester sulfate (PMS) in preparing anti- H1N1 influenza A virus medication. Experiments of the invention prove that PMS not only has great inhibition effect on the neuraminidase of the influenza A virus, but also has relatively good protection effect on canine kidney epithelial cells infected with the H1N1 influenza A virus, and can reduce the replication of the H1N1 virus with an effect that equal to the positive control medication ribavirin. Additionally, the PMS can effectively reduce the death rate of mice infected with the H1N1 influenza A virus and the survival time of the mice are prolonged. The poly mannuronic acid propyl ester sulfate provided by the invention has significant activity of inhibiting the neuraminidase of the H1N1 influenza A virus, and is proved to have good anti- H1N1 influenza A virus activity both in vivo and in vitro experiments, which shows the wide application prospect of the poly mannuronic acid propyl ester sulfate in preparing anti-H1N1 influenza A virus medication.

The invention provides application of mannuronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury. Mannuronic acid oligomers with different molecular weights, which are obtained by degrading polymannuronic acid graded and purified from algin, can lower the hepatosomatic index increase caused by alcoholic injury, resist triglyceride and cholesterol increase caused by alcohol, effectively lower glutamic-pyruvic transaminase and glutamic oxaloacetic transaminase increase in serum caused by alcohol, enhance the total oxidation resistance and glutathione level of the serum, lower the mouse drunkenness rate, prolong the mouse drunkenness time, and shorten the sober-up time, thereby implementing the protective action and hangover alleviating function on alcoholic hepatic injury. The products provided by the invention are derived from marine natural products, have the advantages of abundant resources, high industrialization tendency, high safety, high effectiveness and the like, and have wide development and application prospects in the aspects of prevention and treatment of alcoholic hepatic injury, hangover alleviation and liver protection.

The invention discloses a quality breeding method for sargassum fusiforme. The method comprises the steps that 1, ripe sargassum fusiforme alga bodies are selected to serve as main weeds, the quality ingredients of the main weeds are determined, and the main weeds of which the quality ingredients are in accordance with the following requirements are selected for seedling culturing, wherein the polysaccharide content, by dry weight, of the main weeds is larger than or equal to 40%, and the proportion sum of fucose, guluronic acid and mannuronic acid is larger than or equal to 80% by dry weight of the polysaccharide content of the sargassum fusiforme; 2, after the main weeds which are in accordance with the quality requirements are collected, lower alga bodies of the main weeds are removed, upper and middle alga bodies are retained, a female plant and a male plant are combined into a pair and put in a seedling culturing pool to be cultured for five to eight days, sperms and eggs are released and fertilized to form young embryos, and the young embryos are collected. According to the quality breeding method for the sargassum fusiforme, the breeding effect of the sargassum fusiforme can be significantly improved, the sargassum fusiforme obtained through the breeding method is more uniform in quality and good in breeding effect, the main weeds can be randomly selected for breeding, and the breeding quality of the main weeds is stable.

The invention belongs to the field of natural medicine chemistry and quality control, and relates to a method for measuring the weight-average molecular weight and the content of soluble salt of mannuronic acid substances. Weight-average molecular weight and content results of acid sugar measured by an SEC-MALS (size exclusion chromatography with multi-angle laser scattering detector) are corrected by the aid of the metal ion content of soluble salt samples of the mannuronic acid substances. The weight-average molecular weight and the content of the soluble salt w of the mannuronic acid substances can be rapidly and accurately measured by the method.

The invention belongs to the technical field of a lithium ion battery and particularly relates to a negative electrode of the lithium ion battery. The negative electrode comprises a negative electrode current collector and a negative electrode active substance layer coated on the negative electrode current collector; the negative electrode active substance layer comprises a negative electrode active substance, a conductive agent and a binder; and the binder is alginate, wherein the alginate contains two stereoisomers, i.e. L-guluronic acid (G segment) and D-mannuronic acid (M segment), the ratio of G / M is less than or equal to 1.5, and the content of calcium impurities contained in the alginate is less than or equal to 0.3%. Compared with the prior art, the negative electrode has the advantages that after the alginate is adopted as the binder of the negative electrode of the lithium ion battery, the volume change of the lithium ion battery during the process of lithium de-intercalation can be inhibited, and the binding effect between the negative electrode active substance layer and the binder of the negative electrode is improved, so that the volume expansion coefficient of the battery during the cyclic process is lowered, and the properties of low temperature and multiplying factor of the lithium ion battery are improved. Moreover, the invention further discloses the lithium ion battery containing the negative electrode.

The invention discloses a broad-spectrum flower and fruit protector for plants and application of the broad-spectrum flower and fruit protector. An active component of the broad-spectrum flower and fruit protector adopts alginic acid oligosaccharide or an alginic acid oligosaccharide derivative; the alginic acid oligosaccharide is oligosaccharide obtained by connecting mannuronic acid with guluronic acid through a beta-1,4-glucosidic bond, and the molecular weight of the alginic acid oligosaccharide is 300 to 10,000 Da; the alginic acid oligosaccharide derivative comprises an alginic acid oligosaccharide sulfuric acid derivative and an alginic acid oligosaccharide phosphorus-containing derivative. The broad-spectrum flower and fruit protector is applied to increasing the flower protection and fruit setting rate in growing and developing processes of vegetables and fruit trees; the broad-spectrum flower and fruit protector is applied to the vegetables and the fruit trees. By the use of the broad-spectrum flower and fruit protector, the fruit setting rate can be increased by 40 to 80 percent, and particularly, the fruit setting rate of the vegetables is increased by 30 to 80 percent. A drug with the alginic acid oligosaccharide serving as a main component has the advantages of safety, nontoxicity, low cost, small application amount, environment friendliness, durable effect and the like. The broad-spectrum flower and fruit protector for the plants is used for carrying out application, seed soaking, root dipping, root irrigation and the like on crops such as the fruit trees, so that the flower and fruit protection capacity of the crops can be improved, and the broad-spectrum flower and fruit protector has an outstanding effect on increase of the crop yield and improvement of the quality.

The invention provides oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicine. In in-vitro cell experiments, oligomerization mannuronic acid can obviously promote forming of colony-forming unit-granulocyte macrophage (CFU-GM), simultaneously can promote marrow stroma cells to breed and secrete CFU-GM and promote splenic lymphocytes to secrete interleukin-3. In vivo experiments further indicates that oligomerization mannuronic acid can obviously restrain reduction of white blood cells in mice caused by cyclophosphamide, increase the number marrow nucleated cell of the mice and promote forming of CFU-GM. Experiment results indicate that oligomerization mannuronic acid can be developed to be a clinical medicine capable of effectively preventing leucopenia.